1‘-isobutyl-2H-spiro[isoquinoline-1,4’-piperidin]-3(4H)-one | 15142-90-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: 1‘-isobutyl-2H-spiro[isoquinoline-1,4’-piperidin]-3(4H)-one
• 英文别名: 1a(2)-(2-Methylpropyl)spiro[isoquinoline-1(2H),4a(2)-piperidin]-3(4H)-one；1'-(2-methylpropyl)spiro[2,4-dihydroisoquinoline-1,4'-piperidine]-3-one
• CAS: 15142-90-2
• 化学式: C₁₇H₂₄N₂O
• 分子量: 272.39
• InChiKey: NLIHSWWJGHFQES-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] SPIRO-ISOQUINOLINE-1,4'-PIPERIDINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN<br/>[FR] COMPOSÉS DE SPIRO-ISOQUINOLINE-1,4'-PIPÉRIDINE À ACTIVITÉ MULTIMODALE CONTRE LA DOULEUR
  申请人：ESTEVE LABOR DR

  公开号：WO2016078770A1

  公开（公告）日：2016-05-26

  The present invention relates to spiro-isoquinoline-1,4'-piperidine compounds having dual pharmacological activity towards both the sigma (σ) receptor and the μ-opiod receptor, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.

  本发明涉及具有对σ受体和μ-阿片受体双重药理活性的螺环异喹啉-1,4'-哌啶化合物，以及制备这类化合物的方法，包括含有它们的药物组合物，以及它们在治疗中的应用，特别是用于疼痛治疗。
• Spiro-isoquinoline-1,4′-piperidine compounds having multimodal activity against pain
  申请人：ESTEVE PHARMACEUTICALS, S.A.

  公开号：US10407428B2

  公开（公告）日：2019-09-10

  The present invention relates to spiro-isoquinoline-1,4′-piperidine compounds having dual pharmacological activity towards both the sigma (σ) receptor and the μ-opiod receptor, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.

  本发明涉及对sigma（σ）受体和μ-opiod受体具有双重药理活性的螺-异喹啉-1，4′-哌啶化合物，涉及这种化合物的制备工艺，涉及含有这种化合物的药物组合物，还涉及它们在治疗中的用途，特别是用于治疗疼痛。
• SPIRO-ISOQUINOLINE-1,4'-PIPERIDINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN
  申请人：LABORATORIOS DEL DR. ESTEVE S.A.

  公开号：US20180111935A1

  公开（公告）日：2018-04-26

  The present invention relates to spiro-isoquinoline-1,4′-piperidine compounds having dual pharmacological activity towards both the sigma (σ) receptor and the μ-opiod receptor, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.